94 related articles for article (PubMed ID: 38554158)
1. B7-H3-Targeting Chimeric Antigen Receptors Epstein-Barr Virus-specific T Cells Provides a Tumor Agnostic Off-The-Shelf Therapy Against B7-H3-positive Solid Tumors.
Yeo SP; Kua L; Tan JW; Lim JK; Wong FH; Santos MD; Poh CM; Goh AX; Koh XY; Zhou X; Rajarethinam R; Chen Q; Her Z; Horak ID; Low L; Tan KW
Cancer Res Commun; 2024 Jun; 4(6):1410-1429. PubMed ID: 38717140
[TBL] [Abstract][Full Text] [Related]
2. TOP CAR with TMIGD2 as a safe and effective costimulatory domain in CAR cells treating human solid tumors.
Nishimura CD; Corrigan D; Zheng XY; Galbo PM; Wang S; Liu Y; Wei Y; Suo L; Cui W; Mercado N; Zheng D; Zhang CC; Zang X
Sci Adv; 2024 May; 10(19):eadk1857. PubMed ID: 38718110
[TBL] [Abstract][Full Text] [Related]
3. Chimeric Antigen Receptor T Cell with an Inducible Caspase 9 Suicide Gene Eradicates Uveal Melanoma Liver Metastases via B7-H3 Targeting.
Ventin M; Cattaneo G; Arya S; Jia J; Gelmi MC; Sun Y; Maggs L; Ksander BR; Verdijk RM; Boland GM; Jenkins RW; Haq R; Jager MJ; Wang X; Ryeom S; Ferrone CR
Clin Cancer Res; 2024 May; ():. PubMed ID: 38767611
[TBL] [Abstract][Full Text] [Related]
4. B7-H3-targeted CAR-T cell therapy for solid tumors.
Li G; Wang H; Wu H; Chen J
Int Rev Immunol; 2022; 41(6):625-637. PubMed ID: 35855615
[TBL] [Abstract][Full Text] [Related]
5. B7-H3 and its role in bone cancers.
He L; Li Z
Pathol Res Pract; 2019 Jun; 215(6):152420. PubMed ID: 31060912
[TBL] [Abstract][Full Text] [Related]
6. Targeting osteosarcoma with canine B7-H3 CAR T cells and impact of CXCR2 Co-expression on functional activity.
Cao JW; Lake J; Impastato R; Chow L; Perez L; Chubb L; Kurihara J; Verneris MR; Dow S
Cancer Immunol Immunother; 2024 Mar; 73(5):77. PubMed ID: 38554158
[TBL] [Abstract][Full Text] [Related]
7. Switchable CAR T cell strategy against osteosarcoma.
Hidalgo L; Somovilla-Crespo B; Garcia-Rodriguez P; Morales-Molina A; Rodriguez-Milla MA; Garcia-Castro J
Cancer Immunol Immunother; 2023 Aug; 72(8):2623-2633. PubMed ID: 37062034
[TBL] [Abstract][Full Text] [Related]
8. A Novel Orthotopic Implantation Technique for Osteosarcoma Produces Spontaneous Metastases and Illustrates Dose-Dependent Efficacy of B7-H3-CAR T Cells.
Talbot LJ; Chabot A; Funk A; Nguyen P; Wagner J; Ross A; Tillman H; Davidoff A; Gottschalk S; DeRenzo C
Front Immunol; 2021; 12():691741. PubMed ID: 34211478
[TBL] [Abstract][Full Text] [Related]
9. B7-H3 Specific CAR T Cells for the Naturally Occurring, Spontaneous Canine Sarcoma Model.
Zhang S; Black RG; Kohli K; Hayes BJ; Miller C; Koehne A; Schroeder BA; Abrams K; Schulte BC; Alexiev BA; Heimberger AB; Zhang A; Jing W; Ng JCK; Shinglot H; Seguin B; Salter AI; Riddell SR; Jensen MC; Gottschalk S; Moore PF; Torok-Storb B; Pollack SM
Mol Cancer Ther; 2022 Jun; 21(6):999-1009. PubMed ID: 35405743
[TBL] [Abstract][Full Text] [Related]
10. A high-content screen of FDA approved drugs to enhance CAR T cell function: ingenol-3-angelate improves B7-H3-CAR T cell activity by upregulating B7-H3 on the target cell surface via PKCĪ± activation.
Lee HW; O'Reilly C; Beckett AN; Currier DG; Chen T; DeRenzo C
J Exp Clin Cancer Res; 2024 Apr; 43(1):97. PubMed ID: 38561833
[TBL] [Abstract][Full Text] [Related]
11. CAR T Cells Targeting B7-H3, a Pan-Cancer Antigen, Demonstrate Potent Preclinical Activity Against Pediatric Solid Tumors and Brain Tumors.
Majzner RG; Theruvath JL; Nellan A; Heitzeneder S; Cui Y; Mount CW; Rietberg SP; Linde MH; Xu P; Rota C; Sotillo E; Labanieh L; Lee DW; Orentas RJ; Dimitrov DS; Zhu Z; Croix BS; Delaidelli A; Sekunova A; Bonvini E; Mitra SS; Quezado MM; Majeti R; Monje M; Sorensen PHB; Maris JM; Mackall CL
Clin Cancer Res; 2019 Apr; 25(8):2560-2574. PubMed ID: 30655315
[TBL] [Abstract][Full Text] [Related]
12. Transcriptional profiling of canine osteosarcoma identifies prognostic gene expression signatures with translational value for humans.
Mannheimer JD; Tawa G; Gerhold D; Braisted J; Sayers CM; McEachron TA; Meltzer P; Mazcko C; Beck JA; LeBlanc AK
Commun Biol; 2023 Aug; 6(1):856. PubMed ID: 37591946
[TBL] [Abstract][Full Text] [Related]
13. Strategies to overcome myeloid cell induced immune suppression in the tumor microenvironment.
Cao J; Chow L; Dow S
Front Oncol; 2023; 13():1116016. PubMed ID: 37114134
[TBL] [Abstract][Full Text] [Related]
14. Reprogramming the Canine Glioma Microenvironment with Tumor Vaccination plus Oral Losartan and Propranolol Induces Objective Responses.
Ammons DT; Guth A; Rozental AJ; Kurihara J; Marolf AJ; Chow L; Griffin JF; Makii R; MacQuiddy B; Boss MK; Regan DP; Frank C; McGrath S; Packer RA; Dow S
Cancer Res Commun; 2022 Dec; 2(12):1657-1667. PubMed ID: 36644324
[TBL] [Abstract][Full Text] [Related]
15. Phase 1 study of intraventricular
Kramer K; Pandit-Taskar N; Kushner BH; Zanzonico P; Humm JL; Tomlinson U; Donzelli M; Wolden SL; Haque S; Dunkel I; Souweidane MM; Greenfield JP; Tickoo S; Lewis JS; Lyashchenko SK; Carrasquillo JA; Chu B; Horan C; Larson SM; Cheung NV; Modak S
J Hematol Oncol; 2022 Nov; 15(1):165. PubMed ID: 36371226
[TBL] [Abstract][Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]